Kistler-Tiffany Companies’s Axsome Therapeutics AXSM Stock Holding History

Kistler-Tiffany Companies’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$35.9K	Hold	500	–	–	0.01%	533
2023 Q1	$30.8K	Hold	500	–	–	0.01%	491
2022 Q4	$38.6K	Hold	500	–	–	0.01%	453
2022 Q3	$22K	Hold	500	–	–	0.01%	477
2022 Q2	$19K	Hold	500	–	–	﹤0.01%	508
2022 Q1	$21K	Hold	500	–	–	﹤0.01%	507
2021 Q4	$19K	Hold	500	–	–	﹤0.01%	513
2021 Q3	$16K	Hold	500	–	–	﹤0.01%	528
2021 Q2	$34K	Hold	500	–	–	0.01%	412
2021 Q1	$28K	Hold	500	–	–	0.01%	409
2020 Q4	$41K	Hold	500	–	–	0.01%	323
2020 Q3	$36K	Hold	500	–	–	0.01%	310
2020 Q2	$41K	Hold	500	–	–	0.01%	274
2020 Q1	$52K	Hold	500	–	–	0.02%	252
2019 Q4	$52K	Hold	500	–	–	0.02%	257
2019 Q3	$10K	Hold	500	–	–	﹤0.01%	443
2019 Q2	$13K	Buy	+500	New	+$10K	﹤0.01%	408

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kistler-Tiffany Companies's AXSM Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Axsome Therapeutics (AXSM) position steady in Q2 2023 at 500 shares worth $35.9K. The position accounts for 0.01% of the portfolio, ranked #533.

Kistler-Tiffany Companies first reported a position in AXSM in Q2 2019 and has held it in 17 quarters since. The position peaked at $52K in Q1 2020. 231 funds tracked by Wall St. Rank hold AXSM as of Q2 2023.

Kistler-Tiffany Companies held 500 shares of Axsome Therapeutics worth $35.9K as of Q2 2023.
Kistler-Tiffany Companies left its Axsome Therapeutics share count unchanged in Q2 2023.
Axsome Therapeutics made up 0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #533 holding.
Kistler-Tiffany Companies first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 17 quarters since.
Kistler-Tiffany Companies's Axsome Therapeutics position peaked at $52K in Q1 2020.
231 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.